Company intelligence / Profile preview

NuCana

Edinburgh, Scotland, United Kingdomnucana.com ↗

Ownership: Public · NCNA
Employees: ~75
Development stage: Phase 2

Overview

NuCana’s lead programs are showing encouraging anti-cancer activity in patients with advanced solid tumors and those resistant to prior immunotherapies. NUC‑3373 has demonstrated promising efficacy signals in second-line colorectal cancer and improved inhibition of thymidylate synthase compared to standard 5-FU. NUC‑7738 has shown activity as monotherapy and in combination with pembrolizumab for melanoma patients who failed previous PD‑1 inhibitor therapy. Both agents are advancing through Phase 1b/2 studies.

Therapeutic areas: Oncology
Modalities: small molecules (specifically ProTides—proprietary phosphoramidate nucleoside analogs)
Industry: Biotech

Drug pipeline

6 assets

gemcitabine monophosphate ProTide

5 more assets in the full pipeline.

Request access →

Partnerships

Not explicitly listed; collaboration with Merck for pembrolizumab use in trials implied but not formal partnership disclosed.

Financials

Market cap: $8.5M
Total revenue: $0
Enterprise value: $-10.2M

Beyond the preview

Go deeper on NuCana.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuCana.

Explore the full profile